Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates

Jie Li, Laura Ulitzky, Erica Silberstein, Deborah R. Taylor, Raphael Viscidi

Research output: Contribution to journalArticle

Abstract

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalViral Immunology
Volume26
Issue number2
DOIs
StatePublished - Apr 1 2013

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Virology

Fingerprint Dive into the research topics of 'Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates'. Together they form a unique fingerprint.

  • Cite this